| |
| |
|
| Insider
Information: |
Christensen Jamie |
| Relationship: |
Director |
| City: |
San Diego |
| State: |
CA |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
2 |
|
| Direct
Shares |
40,600 |
|
|
Indirect Shares
|
0 |
|
|
| Direct
Value |
$0 |
|
|
|
Indirect Value
|
$0 |
|
|
| Total
Shares |
40,600 |
|
|
| Total
Value |
$0 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
0
|
14
|
|
Stock
price went up :
|
0
|
3
|
| Stock
price went down : |
0
|
11
|
| |
|
|
|
Gain/Loss Ratio : |
0.0
|
0.0
|
| Percentage
Gain/Loss : |
0.0%
|
 -183.6%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Mirati Therapeutics, Inc. |
MRTX |
|
2024-01-23 |
0 |
2014-12-05 |
0 |
Premium* |
|
|
Tango Therapeutics Ord Shs |
TNGX |
Director |
2020-09-02 |
40,600 |
|
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
61 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 1 of 3
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| TNGX |
Tango Therapeutics Ord Sh... |
Director |
– • – |
2020-09-02 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
40,600 |
|
- |
|
| MRTX |
Mirati Therapeutics, Inc. |
SVP & Chief Scientific Officer |
• – – |
2015-02-17 |
4 |
OE |
$8.50 |
$3,400 |
D/D |
400 |
1,650 |
0 |
- |
|
| MRTX |
Mirati Therapeutics, Inc. |
EVP, Chief Scientific Officer |
• – – |
2021-05-24 |
4 |
S |
$154.34 |
$67,138 |
D/D |
(435) |
53,850 |
0 |
% |
|
| MRTX |
Mirati Therapeutics, Inc. |
EVP & Chief Scientific Officer |
• – – |
2023-05-24 |
4 |
S |
$45.29 |
$28,035 |
D/D |
(619) |
124,123 |
0 |
% |
|
| MRTX |
Mirati Therapeutics, Inc. |
EVP, Chief Scientific Officer |
• – – |
2022-01-18 |
4 |
S |
$120.51 |
$75,558 |
D/D |
(627) |
87,428 |
0 |
% |
|
| MRTX |
Mirati Therapeutics, Inc. |
SVP, Chief Science Officer |
• – – |
2017-09-15 |
4 |
AS |
$12.00 |
$9,240 |
D/D |
(770) |
2,670 |
0 |
- |
|
| MRTX |
Mirati Therapeutics, Inc. |
EVP, Chief Scientific Officer |
• – – |
2021-12-06 |
4 |
S |
$130.78 |
$157,078 |
D/D |
(1,201) |
59,505 |
0 |
% |
|
| MRTX |
Mirati Therapeutics, Inc. |
EVP, Chief Scientific Officer |
• – – |
2022-01-04 |
4 |
S |
$147.72 |
$213,017 |
D/D |
(1,442) |
77,300 |
0 |
% |
|
| MRTX |
Mirati Therapeutics, Inc. |
EVP, Chief Scientific Officer |
• – – |
2021-01-06 |
4 |
S |
$210.28 |
$306,961 |
D/D |
(1,459) |
47,262 |
0 |
% |
|
| MRTX |
Mirati Therapeutics, Inc. |
EVP & Chief Scientific Officer |
• – – |
2024-01-04 |
4 |
S |
$58.81 |
$90,038 |
D/D |
(1,531) |
157,135 |
0 |
% |
|
| MRTX |
Mirati Therapeutics, Inc. |
EVP & Chief Scientific Officer |
• – – |
2024-01-16 |
4 |
S |
$59.02 |
$94,255 |
D/D |
(1,597) |
155,927 |
0 |
% |
|
| MRTX |
Mirati Therapeutics, Inc. |
SVP & Chief Scientific Officer |
• – – |
2015-02-17 |
4 |
AS |
$22.29 |
$37,103 |
D/D |
(1,650) |
1,250 |
0 |
- |
|
| MRTX |
Mirati Therapeutics, Inc. |
EVP, Chief Scientific Officer |
• – – |
2022-12-02 |
4 |
S |
$90.19 |
$155,667 |
D/D |
(1,726) |
104,482 |
0 |
% |
|
| MRTX |
Mirati Therapeutics, Inc. |
EVP, Chief Scientific Officer |
• – – |
2023-01-04 |
4 |
S |
$46.60 |
$90,823 |
D/D |
(1,949) |
100,123 |
0 |
% |
|
| MRTX |
Mirati Therapeutics, Inc. |
EVP, Chief Scientific Officer |
• – – |
2023-01-17 |
4 |
S |
$42.38 |
$95,142 |
D/D |
(2,245) |
97,878 |
0 |
% |
|
| MRTX |
Mirati Therapeutics, Inc. |
EVP & Chief Scientific Officer |
• – – |
2023-12-18 |
4 |
S |
$57.50 |
$137,253 |
D/D |
(2,387) |
141,645 |
0 |
% |
|
| MRTX |
Mirati Therapeutics, Inc. |
EVP & Chief Scientific Officer |
• – – |
2023-09-08 |
4 |
S |
$35.63 |
$85,084 |
D/D |
(2,388) |
144,032 |
0 |
% |
|
| MRTX |
Mirati Therapeutics, Inc. |
EVP, Chief Scientific Officer |
• – – |
2022-12-16 |
4 |
S |
$43.00 |
$103,624 |
D/D |
(2,410) |
102,072 |
0 |
% |
|
| MRTX |
Mirati Therapeutics, Inc. |
SVP & Chief Scientific Officer |
• – – |
2014-12-05 |
4 |
OE |
$8.50 |
$21,250 |
D/D |
2,500 |
2,500 |
0 |
- |
|
| MRTX |
Mirati Therapeutics, Inc. |
SVP & Chief Scientific Officer |
• – – |
2015-02-19 |
4 |
AS |
$23.02 |
$71,376 |
D/D |
(3,100) |
1,250 |
0 |
- |
|
| MRTX |
Mirati Therapeutics, Inc. |
SVP & Chief Scientific Officer |
• – – |
2015-02-19 |
4 |
OE |
$8.50 |
$26,350 |
D/D |
3,100 |
4,350 |
0 |
- |
|
| MRTX |
Mirati Therapeutics, Inc. |
SVP, Chief Science Officer |
• – – |
2017-10-04 |
4 |
AS |
$14.00 |
$56,000 |
D/D |
(4,000) |
2,670 |
0 |
- |
|
| MRTX |
Mirati Therapeutics, Inc. |
SVP, Chief Science Officer |
• – – |
2017-10-04 |
4 |
OE |
$8.50 |
$34,000 |
D/D |
4,000 |
6,670 |
0 |
- |
|
| MRTX |
Mirati Therapeutics, Inc. |
SVP & Chief Scientific Officer |
• – – |
2015-05-26 |
4 |
OE |
$17.41 |
$82,698 |
D/D |
4,750 |
6,000 |
0 |
- |
|
| MRTX |
Mirati Therapeutics, Inc. |
SVP & Chief Scientific Officer |
• – – |
2015-05-26 |
4 |
AS |
$28.03 |
$133,322 |
D/D |
(4,750) |
1,250 |
0 |
- |
|
61 Records found
|
|
Page 1 of 3 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
